Search

Your search keyword '"Koroku, Miki"' showing total 12 results
Start Over Author "Koroku, Miki"
12 results on '"Koroku, Miki"'

3. Efficacy and safety of filgotinib for ulcerative colitis: A real‐world multicenter retrospective study in Japan

Author

Akiyama, Shintaro, primary, Yokoyama, Kaoru, additional, Yagi, Soichi, additional, Shinzaki, Shinichiro, additional, Tsuruta, Kozo, additional, Yoshioka, Shinichiro, additional, Sako, Minako, additional, Shimizu, Hiromichi, additional, Kobayashi, Mariko, additional, Sakurai, Toshiyuki, additional, Nomura, Kei, additional, Shibuya, Tomoyoshi, additional, Takahara, Masahiro, additional, Hiraoka, Sakiko, additional, Sugai, Kyohei, additional, Yanai, Shunichi, additional, Yoshida, Atsushi, additional, Koroku, Miki, additional, Omori, Teppei, additional, Saruta, Masayuki, additional, Matsumoto, Takayuki, additional, Okamoto, Ryuichi, additional, Tsuchiya, Kiichiro, additional, and Fujii, Toshimitsu, additional

Published
2024
Full Text
View/download PDF

10. Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19

Author

Koroku, Miki, primary, Omori, Teppei, additional, Kambayashi, Harutaka, additional, Murasugi, Shun, additional, Kuriyama, Tomoko, additional, Ikarashi, Yuichi, additional, Yonezawa, Maria, additional, Arimura, Ken, additional, Karasawa, Kazunori, additional, Hanafusa, Norio, additional, Kawana, Masatoshi, additional, and Tokushige, Katsutoshi, additional

Published
2021
Full Text
View/download PDF

11. Comparative Efficacy and Safety of Three Janus Kinase Inhibitors in Ulcerative Colitis: A Real‐World Multicentre Study in Japan.

Author

Akiyama, Shintaro, Shimizu, Hiromichi, Tamura, Akiko, Yokoyama, Kaoru, Sakurai, Toshiyuki, Kobayashi, Mariko, Eizuka, Makoto, Yanai, Shunichi, Nomura, Kei, Shibuya, Tomoyoshi, Takahara, Masahiro, Hiraoka, Sakiko, Sako, Minako, Yoshida, Atsushi, Tsuruta, Kozo, Yoshioka, Shinichiro, Koroku, Miki, Omori, Teppei, Saruta, Masayuki, and Matsumoto, Takayuki

Subjects
*ULCERATIVE colitis, *DISEASE remission, *KINASE inhibitors, *MULTIVARIATE analysis, *COMPARATIVE studies
Abstract

ABSTRACT Background Aim Methods Results Conclusions Three Janus kinase (JAK) inhibitors are approved for ulcerative colitis (UC) in Japan.To compare the real‐world efficacy and safety of these three JAK inhibitors in UC.This was a multicentre, retrospective study of patients with UC started on JAK inhibitors. The primary outcome was clinical remission at 10, 26 and 58 weeks, and at the most recent follow‐up. To compare the efficacy and safety among the JAK inhibitors, we created three matched cohorts (upadacitinib vs. filgotinib, tofacitinib vs. filgotinib and upadacitinib vs. tofacitinib) using propensity score matching.We identified 228 upadacitinib‐treated patients (median follow‐up 49 weeks; IQR 25–72), 215 filgotinib‐treated patients (follow‐up 56 weeks; IQR 17–82) and 159 tofacitinib‐treated patients (follow‐up 112 weeks; IQR 10–258). Clinical remission rates for upadacitinib, filgotinib and tofacitinib at the most recent follow‐up were 72.8%, 50.6% and 45.8%, respectively. Over 70% of the patients previously treated with other biologics or JAK inhibitors achieved clinical remission with upadacitinib. On multivariate analysis, the number of previous advanced therapies was inversely associated with the efficacy of filgotinib and tofacitinib. Comparative analysis showed that upadacitinib‐treated patients had higher efficacy and lower risk of discontinuation than patients treated with other JAK inhibitors. However, upadacitinib had a significant risk of acne.Considering the particularly high efficacy of upadacitinib, even in patients with refractory UC, filgotinib or tofacitinib may be considered as an upfront JAK inhibitor before using upadacitinib. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19: a case report.

Author

Koroku M, Omori T, Kambayashi H, Murasugi S, Kuriyama T, Ikarashi Y, Yonezawa M, Arimura K, Karasawa K, Hanafusa N, Kawana M, and Tokushige K

Abstract

Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is now a pandemic. Although several treatment guidelines have been proposed for patients who have both inflammatory bowel disease and COVID-19, immunosuppressive therapy is essentially not recommended, and the treatment options are limited. Even in the COVID-19 pandemic, adjuvant adsorptive granulocyte and monocyte apheresis may safely bring ulcerative colitis (UC) into remission by removing activated myeloid cells without the use of immunosuppressive therapy. Our patient was a 25-year-old Japanese male with UC and COVID-19. This is the first case report of the induction of UC remission with granulocyte and monocyte apheresis treatment for active UC associated with COVID-19.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results